Objective: To evaluate prognostic factors and tumor staging in patients after esophagectomy for cancer. Summary Background Data: Several reports have questioned the appropriateness of the sixth edition of the International Union Against Cancer (UICC) TNM guidelines for staging esophageal cancer. Additional pathologic characteristics, besides the 3 basic facets of anatomic spread (tumor, node, metastases), might also have prognostic value. Methods: All patients who underwent resection of the esophagus for carcinoma between January 1995 and March 2003 were extracted from a prospective database. Univariate and multivariate analysis was performed to identify prognostic factors for survival. The goodness of fit and accuracy of 3 staging models (UICC-TNM, Korst classification, Rice classification) predicting survival were assessed. Results: A total of 292 patients (mean age, 63 years) underwent esophagectomy. The 5-year overall survival rate was 29% (median, 21 months). pT-, pN-, pM-stage, and radicality of the resection were independent prognostic factors. Subdivision of T1 tumors into mucosal and submucosal showed significant differences in 5-year survival between both groups: 90% versus 47%, respectively (P ϭ 0.01). Subdivision of pN-stage into 3 groups based on the number of positive nodes (0, 1-2, and Ͼ3 nodes positive) or the lymph node ratio (0, 0.01-0.2, and Ͼ0.2) also refined staging (P ϭ 0.001 and P Ͻ 0.001, respectively). The current subclassification of M1 (M1a and M1b) is not warranted (P ϭ 0.41). The staging model of Rice was more accurate than the UICC-TNM classification in predicting survival. Conclusion: This study supports the view that the current (6th edition) UICC-TNM staging model for esophageal cancer needs to be revised.
B etween 1943 and 1952, the Frenchman Pierre Denoix developed the TNM system for the classification of malignant tumors. 1 Soon thereafter, in 1958, the first recommendations for the clinical stage classification of cancers were published by the UICC committee on Clinical Stage Classification and Applied Statistics. 2 In the year 2002, the 6th edition with the latest recommendations for classification of cancers was released by the International Union Against Cancer (UICC). This included the staging classification for esophageal cancer. 3 One important objective of TNM staging is to give an as accurate possible indication of prognosis. 4 For the classification of esophageal cancer, however, there is an ongoing debate about revision of the current guidelines, driven by surgeons who think that it does not stratify patients appropriately for prognosis. [5] [6] [7] [8] For example, a strong plea has been made to redefine the T1 stage into pT1a (intramucosal) and pT1b (submucosal) tumors and to use the number of tumorpositive nodes for staging, since both indicators have been shown to refine the TNM staging system. 6,9 -11 Furthermore, the subdivision of distant metastatic disease into nonregional lymph node metastases (M1b) and other metastases (M1a) seems, at least from a clinical perspective, not appropriate. 12 Also, several pathologic characteristics of the primary tumor, including tumor length, perineural invasion, and vaso-invasive growth, have been shown to correlate with outcome after treatment of esophageal cancer [13] [14] [15] In this study, we tried to address these issues by evaluating outcome in relation to several prognostic factors and different staging classifications in a well-defined homogeneous cohort of patients who underwent esophagectomy for cancer.
METHODS

Study Population
The Erasmus MC in Rotterdam is a tertiary referral center for patients with benign and malignant diseases of the upper gastrointestinal tract in the South West of the Netherlands. Since January 1978, outcome data for all patients with esophageal cancer referred to our hospital for further analysis and treatment were collected prospectively and stored in a database by a data manager. The data collected encompassed all relevant diagnostic tests, scheduled treatments, and pathology. Between January 1, 1978 and March 31, 2003 , 2369 patients were entered into the database. For this study, only patients who underwent resection of the esophagus for inva-sive carcinoma involving the esophagus or gastroesophageal junction (Siewert type I and II) 16 were evaluated. Because endoscopic ultrasonography for evaluation of T-stage and nodal status was routinely performed as a staging modality since January 1995 in our hospital, this date was chosen as starting date for the study. All operations were performed or closely supervised by 2 senior consultant surgeons (K.T.C.T., H.W.T.). To obtain a homogeneous cohort of patients in terms of treatment and to circumvent possible stage migration following chemoradiation therapy, patients receiving neoadjuvant therapy were excluded from this analysis ( Fig. 1 ).
Surgery
Resection of the esophagus and gastric cardia was usually performed via the transhiatal technique when the tumor was located below the level of the tracheal bifurcation, as described previously. 17, 18 A thoracotomy was performed when the tumor was located in the middle or upper third of the intrathoracic esophagus. In all patients, a standard dissection of perigastric, left gastric, and celiac nodes was performed. Macroscopic tumor clearance was sought in all cases, but no extended lymph node dissection was done. When possible, the continuity of the gastrointestinal tract was restored by creating a stomach tube with cervical end-to-side esophagogastrostomy.
Pathology
Data on patients' characteristics, details of the surgical procedures, and pathology of the resection specimens were extracted from the database. Gross specimens were processed according to a standard laboratory protocol. Multiple 4-m sections of the tumor and surrounding mucosa were taken and stained with hematoxylin and eosin. For the purpose of this study, all pathology records of the resection specimens were reviewed with special emphasis to the number of lymph nodes present. The total number of lymph nodes identified was recorded, as well as the number of lymph nodes involved by tumor. Subsequently, the lymph node ration (LNR) was calculated as the number of positive lymph nodes divided by the total number of resected nodes. The pathology report also included information regarding the presence of Barrett's epithelium, defined as the presence of intestinal type metaplasia with the presence of goblet cells within the tubular esophagus. Vaso-invasive growth was assessed on the basis of infiltration of the venous or arterial system, or the presence of tumor emboli. When cancer cells infiltrated into the perineurium or neural fasciculus, perineural growth was noted. The resection was considered to be microscopically incomplete when tumor cells were present less than 1 mm from the plane of resection (ie, the circumferential margin). Grade of differentiation of the tumor was assessed and classified as either well, moderately, poorly/undifferentiated. Furthermore, the presence of signet ring cell differentiation was noted separately. The carcinomas were staged according to the latest pTNM criteria for carcinoma of the esophagus, established by the UICC in 2002. 3 patients. Overall survival was calculated from the date of operation according to the Kaplan-Meier method and included perioperative deaths. Overall survivals were compared across the levels of prognostic factors with the log-rank test. Multivariate analyses were performed by Cox regression. To determine the optimal cutoff point for the number of involved nodes as well as the lymph node ratio as predictors of survival, the relationship between the number of positive nodes as well as the lymph node ratio and death from esophageal cancer was investigated using a scatter plot of these both variables versus Martingale residuals from a Cox proportional hazards regression model without the variable of interest. A smoothed fit of the scatter was then applied to detect the optimal cut off point. 19 To compare the "goodness of fit" of different staging models with respect to overall survival (UICC TNM stage grouping, Korst and Rice classifications, and 3 models of nodal involvement), the Bayesian Information Criterion (BIC) was calculated for each model. A lower value for the BIC indicates a better fit. 20 Harrell's C was calculated to explore which staging model was most accurate in predicting survival. A value closer to 1 represents better diagnostic accuracy. 21 All statistical tests were two-sided. Statistical significance was set at the 5% level. Calculations were conducted with SPSS version 12.0.1 (Chicago, IL), and Stata version 9.1 (College Station, TX).
RESULTS
Patients
A total of 292 patients, mean age of 63 years (range, 33-83 years), underwent resection with curative intent for invasive esophageal cancer. There were 48 women (16%) and 244 men (84%). Weight loss Ͼ5% at time of presentation was present in 42% of the patients, whereas 58% did not report any or less than 5% loss of body weight. Loss of more than 5% of body weight was associated with a poor outcome ( Table 1 ). More than half of the patients (61%) had symptoms for at least 2 months before the tumor was diagnosed.
Operation and Outcome of Surgery
Resection of the esophagus and gastric cardia was performed via the transhiatal technique in 84% of the patients, and continuity of the gastrointestinal tract was restored by creating a stomach tube in 98% of the patients. A colonic interposition was performed in 7 patients. The median length of hospital stay was 14 days (range, 6 -136 days). The 30-day mortality was 2.7% (8 patients), and the in-hospital mortality rate was 5.8% (17 patients).
Follow-up was complete for all 292 patients. The overall 3-and 5-year survival rates were 38% and 29%, respectively, with a median survival of 21 months.
Pathology and Tumor Stage
The distribution of the tumors according to pathologic characteristics, tumor stage, and stage grouping according to the UICC-TNM 2002 criteria is shown in Tables 1 and 2.
Prognostic Factors
Several clinical variables as well as pathologic characteristics of the tumors predicting 5-year overall survival could be identified (Tables 1, 2 ). Loss of more than 5% of body weight and having symptoms of dysphagia were associated with poorer survival. However, this could largely be explained by the fact that these patients were more likely to have a more advanced TNM stage (cross tabulation; 2 test, P ϭ 0.0001). pT-, pN-, pM-, and pTNM stage grouping were all predictors of survival. Patients with mucosal (pT1a) tumors had a significant better outcome than tumors infiltrating in the submucosa (pT1b). There was no difference in site of first recurrence between pT1a and pT1b tumors. No difference in survival was observed between pM1a and pM1b tumors (P ϭ 0.414).
Also, the number of positive lymph nodes as well as the LNR were associated with overall survival. To determine the optimal cutoff point for the number of lymph nodes positive, the Martingale residuals of the Cox model (including the variables pT-stage, pM-stage, grade of differentiation, and radicality of the resection) were first calculated and then plotted against the number of positive nodes (Fig. 2 ). From this figure, it appears that the cutoff value is a number of 3 positive nodes. The same calculations were done for the LNR, and this resulted in a cutoff value of 0.2. Survival curves for patients after esophagectomy in relation to the number of positive lymph nodes and the LNR are shown in Figures 3 and 4 , respectively.
To identify independent prognostic variables predicting survival after surgery for cancer, Cox regression analysis was performed. The results are presented in Table 3 . TNM stages and stage grouping were independently associated with survival.
Stage Grouping
Survival according to the UICC 2002 TNM stages is shown in Figure 5 . No significant differences in survival were noted only between the stages III and IV (P ϭ 0.15). Figure  6 shows the survival for all 292 patients when staging is performed according to the proposed revised staging classification of Korst et al. 7 Differences in survival were significant between all groups. When the tumors were staged according to the model proposed by Rice et al, a separation into groups with significant different survival rates was also noted, except for stage II tumors versus stage III tumors (P ϭ 0.08; Fig. 7 ). Goodness of fit of the UICC-TNM stage grouping, the Korst and Rice classifications was calculated as well as the accuracy in predicting survival of the 3 models ( Table 4 ). The Rice model turned out to have the best fit to the data (lowest BIC). This model also has the highest Harrell's C, which indicates that this model has the highest accuracy in predicting survival. The same calculations were performed for the 3 different stage models that classify lymph node involvement.
geons, oncologists, and other physicians, is of crucial importance. Not only does it provide an indication of the patient's prognosis, but it also aids the clinician in the planning of treatment, assists in the evaluation of the results of treatment, and facilitates the exchange of information between different centers. 4 The TNM system for classifying the anatomic extent of disease in cancer has been in existence for more than 50 years. With time and sequential editions, the TNM classification has evolved to accommodate new knowledge. However, whereas in the early days of the TNM classification only 3 basic facets of anatomic spread were assessed, we now face an enormous increase in knowledge of, for example, the genetics of cancer. In 2001 Leslie Sobin, chairman of the TNM prognostic factors project of the UICC, wrote: "the most important challenge facing the TNM is how to interface with the great numbers of non anatomic prognostic factors that are currently in use or under study." 4 This statement seems also true for the staging of esophageal cancer, as new nonanatomic prognostic factors and data on the molecular biology of esophageal cancer and their possible relation with tumor stage and outcome emerge. [22] [23] [24] [25] For example, tumor length, perineural and vaso-invasive growth, histologic type, and presence of Barrett's metaplasia have been shown to correlate with outcome in patients after resection for esophageal cancer. 13,14,26 -28 However, there is a risk that the TNM will be overwhelmed by such a variety of prognostic factors and that this will increase the complexity of staging. 4 In addition, other studies have not demonstrated the independent prognostic value of (some of) the variables. 29 -31 Differences between study populations, inclusion criteria, statistical analysis, and the retrospective design of most studies, probably contribute to this controversy. 32 Recently, the UICC-TNM committee decided to establish guidelines for the submission and evaluation of proposed changes to the TNM system, to improve the quality of the evidence provided. 32 Many proposals for revision of the TNM classification published in international journals, how-ever, seem to often lack the information required. We evaluated several prognostic factors in a well-defined and homogeneous group of patients with esophageal cancer treated by surgical resection alone. Our data do not support incorporation of aforementioned pathologic characteristics into the current UICC-TNM staging.
TNM was constructed to assess only the 3 basic indicators of anatomic spread. We have demonstrated that these robust indicators of the TNM staging system (in particular pT-and pN-stage) are indeed the most important predictors of 5-year survival, although we think that refinement of the current UICC-TNM system is necessary. In an earlier study, it has been shown that subclassification of pT1 tumors is of clinical importance. 33 Tumors limited to the submucosa rarely metastasize to lymph nodes and have an excellent prognosis. This might also influence therapeutic decision making. 6, 28, 34 In our study, subdivision of pT1 tumors according to these criteria had a significant impact on survival, supporting the views of many who also favor reclassification of pT1 stage into mucosal and submucosal tumors. 6, 35, 36 Involvement of regional lymph nodes is another robust predictor of survival after surgery for esophageal cancer, and this is acknowledged in the current TNM classification. However, within the group of patients with positive locoregional nodes, survival is not homogeneous and a further subdivision can be made based on the extensiveness of lymph node involvement. 6 This can be expressed as either the total number of positive nodes or the number of positive nodes divided by the total number of resected nodes (ie, LNR). The feasibility of this subdivision has already been shown by others. 13, 37, 38 However, the number of positive nodes and the LNR differ substantially among the published series. Furthermore, it is unclear from most studies what calculations were performed to retrieve the optimal cutoff point. 9 -11,39 By calculating the Martingale residuals, we found that the cutoff should be around 3 positive nodes. Our findings are similar to the observations made by Rice et al, who subclassified their node-positive patients as N1 (Յ2 metastatic nodes) and N2 (Ն3 metastatic nodes) and also demonstrated significant different survival rates. The lymph node ratio has also been reported to be a predictor of survival and, again, various ratios have been proposed. 9,10,37,40 A plausible explanation for the apparent discrepancy has been put forward by Nigro et al 9 : a more extensive lymphadenectomy results in a greater number of uninvolved nodes removed, thereby driving down the LNR. The median number of removed nodes was indeed different between 2 studies reporting different ratios: 26 versus 51 in the study of Hölscher and Nigro, with reported ratios of 0.1 and 0.3, respectively. 9, 40 The median number of lymph nodes resected in our study was substantially less (a median number of 11) and probably relates to the high percentage of transhiatal resections (84%). However, we calculated a LNR of 0.2 to be highly discriminative in predicting the likelihood of survival. This is also the first study that calculated and compared the goodness of fit and accuracy of UICC pN-stage, number of positive nodes, and LNR. Our data do indicate that the lymph node ratio better fits the data and might be the best discriminator. However, pN-stage still showed to be more accurate in predicting survival. Clearly, more studies are needed to confirm this findings before true recommendations can be made. Predictably the 5-year survival of patients with M1a disease was similar to that of patients with M1b disease. This is similar to another report. 6 Survival in patients with M1a nodal involvement is actually very similar to the survival curve for patients with stage III disease. This observation is similar to the findings of Hulscher et al who found no significant difference in survival between stage III and stage IV tumors and the study of Korst et al who proposed M1a nodal disease to be reclassified as N2M0. 7, 41 Although a small but significant difference in survival between M1a and M1b was present in the retrospective study of Christie et al, these differences could be explained by differences in treatment between M1a and M1b patients. They concluded that, at least from a clinical point of view, this distinction is unimportant. 12 In our study, the accuracy and predictability of 3 different stage groupings were assessed. Korst et al propose to reclassify tumors designated as N1M1 in the 3rd edition of the UICC system because of lymph node metastases beyond the regional nodes as N2M0. As a consequence of this, stage IV disease represents only patients with pT4 tumors and patients with visceral metastases. 7 Although we can support the N2M0 classification by showing equal survival between stage III and stage IV disease, the number of patients assigned to stage IV disease in their study was very small; therefore, these results must be interpreted with caution. Additionally, 15% of their patients received preoperative radiation and/or chemotherapy, and this almost certainly influenced postoperative staging in some patients.
Our analysis shows that staging according to the model of Rice is accurate and is the best predictor of survival. The 5-year stage-specific survival rates of our patients are similar to the rates presented by Rice et al. 6 Maybe this is not surprising since our study also excluded patients who received some form of chemotherapy and/or radiotherapy. Furthermore, the median number of resected lymph nodes is similar to ours, and all cause mortality from time of esophagectomy was also used to calculate survival estimates.
Of interest is the recent study of Lerut et al, 42 who showed that extracapsular lymph node involvement is a negative prognostic factor in advanced esophageal cancer. Patients with intracapsular lymph node involvement had a similar survival rate to true N0 patients, and extracapsular lymph node involvement was a bad prognostic factor, even independent of the number of involved nodes. However, only T3 tumors and R0 resections were included in this analysis. Unfortunately, we were unable to get complete and detailed information about intracapsular or extracapsular involvement of lymph nodes in our patient cohort, since this is not routinely registered in our institution. A further evaluation of the role of intracapsular and extracapsular lymph node involvement in a prospective cohort of patients, including early stage (ϽpT3) and R1 resected cancers, is warranted before any additional value in the staging of esophageal cancer patients can be assigned to this parameter.
However, it might become increasingly difficult to conduct such a prospective study. It is our experience that many patients nowadays receive neoadjuvant chemotherapy or chemoradiation. This means that accurate assessment of the primary tumor and lymph nodes, and as a consequence pTNM stage, might be hampered, although Swisher et al reported that despite pathologic downstaging, overall survival was still well predicted by the pTNM staging system. 43 The response of the tumor to chemoradiation, as determined by histopathologic examination of the resection specimen, was also an independent predictor of survival in their study and a modified esophageal cancer TNM staging system was proposed. But addition of a fourth factor (response to chemoradiation) to the staging system brings the number of stage groups to 18, and this makes its application only more complicated.
CONCLUSION
Proposals for changes to the TNM classification for esophageal cancer vary widely in their format and content, and frequently provide insufficient information or fail to properly assess the value or validity of the proposed changes. Proposals also often lack consistency in the amount and quality of supporting data submitted. A clear and concise description of the patient cohort, referral pattern, selection process, TNM classification, endpoints used, and statistical methods used are all important. 32 In our study, we tried to address these issues by carefully selecting a homogeneous cohort of patients and avoiding influences of multimodality therapy. We showed that: 1) pT1 tumors can be subgrouped FIGURE 7 . Survival according to classification of Rice et al. 6 No significant difference in survival between stage II and II (P ϭ 0.08). Explanation of the N-and M-classifications: N0, no positive nodes; N1, 1 or 2 nodes positive; N2, 3 or more nodes positive; M0, no distant metastases; M1, distant metastases (nodal and/or organ involvement). Stage I, Tis-1aN0M0; stage II, T1bN0M0/T1aN1M0/T2N0M0; stage III, T3N0M0/T1b-2N1M0/T3N1M0/T4N0M0; stage IV, T4 N1M0/anyTN2M0, anyM1. 
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